Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury
Romain Marignier(Hospices Civils de Lyon), Pascale Giraudon(Université Claude Bernard Lyon 1)
Cited by 179
Related Papers
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Myelin-oligodendrocyte glycoprotein antibody-associated disease
|The Lancet Neurology|2021|518
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
|Frontiers in Neurology|2020|399
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
|The Lancet Neurology|2025|314
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303